He previously served as VP Preclinical Development at Dermira Inc. following its acquisition of Valocor Therapeutics in 2011. She co-founded Valocor in 2008, leading that company’s major R&D programs from inception as VP Project Direction/Operations. She previously served as Senior Director Project Management at QLT, managing all development activities including manufacturing, preclinical, clinical, regulatory affairs. She also served as Director of Clinical Research, leading Phase 1 and Phase 2 clinical development activities. Agnes received her PhD in Immunology from the University of British Columbia and completed her postdoctoral training at the Ontario Cancer Institute. He previously served as VP Preclinical Development at Dermira Inc. following its acquisition of Valocor Therapeutics in 2011. She co-founded Valocor in 2008, leading that company’s major R&D programs from inception as VP Project Direction/Operations. She previously served as Senior Director Project Management at QLT, managing all development activities including manufacturing, preclinical, clinical, regulatory affairs. She also served as Director of Clinical Research, leading Phase 1 and Phase 2 clinical development activities. Agnes received her PhD in Immunology from the University of British Columbia and completed her postdoctoral training at the Ontario Cancer Institute.

Phase 1 and Phase 2 clinical development, Oncology